Literature DB >> 32419940

High-dose methotrexate-induced fulminant hepatic failure and pancytopenia in an acute lymphoblastic leukaemia paediatric patient.

Manjusha Sajith1, Atmaram Pawar1, Vibha Bafna2, Sandip Bartakke3.   

Abstract

Methotrexate treatment has been associated with an array of liver-related adverse events like asymptomatic transaminase elevations, fatal necrosis and fibrosis. Here we present a child with relapse Pre B cell acute lymphoblastic leukaemia who developed and died of fulminant hepatic failure and pancytopenia soon after the administration of high-dose MTX. This case is unusual due to a series of adverse events that led to severe toxicity. The child received 1 g/m2 dose of methotrexate infusion for 36 hours. The patient developed drowsiness with altered sensorium in the 72 hours after starting the infusion. Investigations revealed severe pancytopenia along with grossly deranged liver function tests and coagulation profile. On the fourth day of paediatric intensive care unit admission, the child went into cardiac arrest and could not be revived. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  fulminant hepatic failure; high dose methotrexate infusion; pancytopenia; relapse

Mesh:

Substances:

Year:  2019        PMID: 32419940      PMCID: PMC7223351          DOI: 10.1136/ejhpharm-2019-001944

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  7 in total

Review 1.  Understanding and managing methotrexate nephrotoxicity.

Authors:  Brigitte C Widemann; Peter C Adamson
Journal:  Oncologist       Date:  2006-06

2.  Fulminant hepatic failure caused by Salmonella paratyphi A infection.

Authors:  Fahmi Yousef Khan; Ahmed A Kamha; Ibrahim Y Alomary
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

3.  Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment.

Authors:  Katerina Katsimpardi; Vassilios Papadakis; Anastasia Pangalis; Agapi Parcharidou; John P Panagiotou; Michael Soutis; Evangelos Papandreou; Sophia Polychronopoulou; Stavros Haidas
Journal:  Support Care Cancer       Date:  2005-11-04       Impact factor: 3.603

Review 4.  Role of reactive metabolites in drug-induced hepatotoxicity.

Authors:  A Srivastava; J L Maggs; D J Antoine; D P Williams; D A Smith; B K Park
Journal:  Handb Exp Pharmacol       Date:  2010

5.  A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.

Authors:  Elio Castagnola; Vincenzo Fontana; Ilaria Caviglia; Silvia Caruso; Maura Faraci; Francesca Fioredda; Maria Luisa Garrè; Cristina Moroni; Massimo Conte; Giuseppe Losurdo; Franca Scuderi; Roberto Bandettini; Paolo Tomà; Claudio Viscoli; Riccardo Haupt
Journal:  Clin Infect Dis       Date:  2007-10-05       Impact factor: 9.079

6.  Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: A retrospective analysis from a single center.

Authors:  Arun B Karanwal; Bharat J Parikh; Parijat Goswami; Harsha P Panchal; Bhavesh B Parekh; Kaushal B Patel
Journal:  Indian J Med Paediatr Oncol       Date:  2013-04

Review 7.  Risk of liver disease in methotrexate treated patients.

Authors:  Richard Conway; John J Carey
Journal:  World J Hepatol       Date:  2017-09-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.